SG10202010735PA - Tau-binding antibodies - Google Patents

Tau-binding antibodies

Info

Publication number: SG10202010735PA
Authority: SG; Singapore
Prior art keywords: tau; binding antibodies; antibodies; binding
Prior art date: 2015-07-06

Application number

SG10202010735PA

Other languages

English (en)

Inventor

David Edward Ormonde Knight

Terence Seward Baker

David James Mcmillan

Robert Anthony Griffin

Georges Mairet-Coello

Patrick Downey

Jean-Philippe Courade

Original Assignee

UCB Biopharma SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-07-05

Publication date

2020-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53524640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202010735P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-07-05 Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL

2020-11-27 Publication of SG10202010735PA publication Critical patent/SG10202010735PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hospice & Palliative Care (AREA)
Animal Behavior & Ethology (AREA)
Psychiatry (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10202010735PA 2015-07-06 2016-07-05 Tau-binding antibodies SG10202010735PA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP15175522		2015-07-06

Publications (1)

Publication Number	Publication Date
SG10202010735PA true SG10202010735PA (en)	2020-11-27

Family

ID=53524640

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10202010735PA SG10202010735PA (en)	2015-07-06	2016-07-05	Tau-binding antibodies

Country Status (27)

Country	Link
US (4)	US10287343B2 (es)
EP (1)	EP3319983A1 (es)
JP (3)	JP6630426B2 (es)
KR (1)	KR20180025962A (es)
CN (1)	CN107849104B (es)
AR (1)	AR105267A1 (es)
AU (1)	AU2016289755C1 (es)
BR (1)	BR112017028102A2 (es)
CA (1)	CA2991451A1 (es)
CL (1)	CL2018000043A1 (es)
CO (1)	CO2017012971A2 (es)
EA (1)	EA037092B1 (es)
EC (1)	ECSP18000887A (es)
HK (1)	HK1246804A1 (es)
IL (1)	IL256685B (es)
MA (2)	MA41670A1 (es)
MX (1)	MX2017015817A (es)
MY (1)	MY193677A (es)
PE (1)	PE20180481A1 (es)
PH (1)	PH12017502207A1 (es)
SG (1)	SG10202010735PA (es)
TN (1)	TN2017000539A1 (es)
TW (1)	TWI745295B (es)
UA (1)	UA124616C2 (es)
UY (1)	UY36773A (es)
WO (1)	WO2017005734A1 (es)
ZA (1)	ZA201800027B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA126272C2 (uk)	2015-06-05	2022-09-14	Дженентек, Інк.	Антитіло проти тау-білка та спосіб його застосування
KR20180025962A (ko)	2015-07-06	2018-03-09	유씨비 바이오파마 에스피알엘	타우 결합 항체
KR20180027566A (ko)	2015-07-06	2018-03-14	유씨비 바이오파마 에스피알엘	타우 결합 항체
WO2018106776A2 (en)	2016-12-07	2018-06-14	Genentech, Inc.	Anti-tau antibodies and methods of use
MX2019006334A (es)	2016-12-07	2019-08-01	Genentech Inc	Anticuerpos antitau y métodos de uso.
KR20190134997A (ko)	2017-02-17	2019-12-05	데날리 테라퓨틱스 인크.	항-tau 항체 및 이의 사용 방법
JP2018139530A (ja)	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
KR102225178B1 (ko)	2017-10-16	2021-03-10	에자이 알앤드디 매니지먼트 가부시키가이샤	항-타우 항체 및 그의 용도
US20220017611A1 (en) *	2018-12-13	2022-01-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	New anti tau svqivykpv epitope single domain antibody
EP4013772A4 (en) *	2019-08-13	2024-06-05	Washington University	METHODS FOR DETECTING MTBR-TAU ISOFORMS AND THEIR USE
JP7399305B2 (ja)	2020-02-12	2023-12-15	イーライリリーアンドカンパニー	抗体または抗原結合フラグメントの結晶化
AU2021297873A1 (en)	2020-06-25	2023-02-09	Merck Sharp & Dohme Llc	High affinity antibodies targeting tau phosphorylated at serine 413
WO2023092004A1 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2024107745A1 (en) *	2022-11-14	2024-05-23	Washington University	Methods to detect csf mtbr-tau and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en)	1994-04-26	2002-04-16	Genetics Institute, Inc.	Formulations for factor IX
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
US6566329B1 (en)	1999-06-28	2003-05-20	Novo Nordisk A/S	Freeze-dried preparation of human growth hormone
AT500379B8 (de) *	2001-02-02	2009-08-15	Axon Neuroscience	Tau-proteine
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
HUE026278T2 (en)	2003-07-01	2016-05-30	Ucb Biopharma Sprl	Modified Fab antibody fragments
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
CN1721437A (zh) *	2004-07-13	2006-01-18	中南大学	一种与Tau蛋白相关的多肽抗原及抗体
NZ597168A (en)	2005-08-19	2013-07-26	Abbott Lab	Dual variable domain immunoglobin and uses thereof
GB0614780D0 (en)	2006-07-25	2006-09-06	Ucb Sa	Biological products
GB0619291D0 (en)	2006-09-29	2006-11-08	Ucb Sa	Altered antibodies
GB0624500D0 (en) *	2006-12-07	2007-01-17	Istituto Superiore Di Sanito	A novel passive vaccine for candida infections
WO2009040562A1 (en)	2007-09-26	2009-04-02	Ucb Pharma S.A.	Dual specificity antibody fusions
CN101307108B (zh) *	2008-06-25	2012-04-04	南京川博生物技术有限公司	抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
HUE033438T2 (en)	2008-09-26	2017-11-28	Ucb Biopharma Sprl	Biological products
CN102245642A (zh)	2008-10-15	2011-11-16	安吉奥开米公司	Glp-1激动剂的结合物及其用途
EP2370472A4 (en)	2008-12-05	2013-04-24	Angiochem Inc	LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES
US9914754B2 (en)	2008-12-05	2018-03-13	Angiochem Inc.	Conjugates of neurotensin or neurotensin analogs and uses thereof
US8609097B2 (en) *	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
ES2667258T3 (es)	2009-09-10	2018-05-10	Ucb Biopharma Sprl	Anticuerpos multivalentes
EP2486061A4 (en)	2009-10-06	2013-08-28	Angiochem Inc	COMPOSITIONS AND METHODS FOR THE TRANSPORT OF THERAPEUTICS
AU2011311516B2 (en)	2010-10-07	2015-06-11	Ac Immune S.A.	Phosphospecific antibodies recognising Tau
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
EP2758433B1 (en)	2011-09-19	2017-10-18	Axon Neuroscience SE	Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
MX351502B (es)	2011-11-11	2017-10-18	Ucb Pharma Sa	Anticuerpos de union de albumina y fragmentos de union de los mismos.
MY178142A (en) *	2011-12-20	2020-10-05	Janssen Biotech Inc	Anti-phf-tau antibodies and their uses
KR20200013072A (ko)	2012-07-03	2020-02-05	워싱턴 유니버시티	Tau에 대한 항체
ES2775192T3 (es) *	2012-08-16	2020-07-24	Ipierian Inc	Procedimientos de tratamiento de una tauopatía
EA035932B1 (ru)	2012-12-21	2020-09-02	Байоджен Ма Инк.	Человеческие анти-тау антитела
CA2874083C (en) *	2014-12-05	2024-01-02	Universite Laval	Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
KR20180025962A (ko)	2015-07-06	2018-03-09	유씨비 바이오파마 에스피알엘	타우 결합 항체
KR20180027566A (ko)	2015-07-06	2018-03-14	유씨비 바이오파마 에스피알엘	타우 결합 항체

2016
- 2016-07-05 KR KR1020187003689A patent/KR20180025962A/ko not_active Application Discontinuation
- 2016-07-05 JP JP2018500423A patent/JP6630426B2/ja active Active
- 2016-07-05 AU AU2016289755A patent/AU2016289755C1/en active Active
- 2016-07-05 TN TNP/2017/000539A patent/TN2017000539A1/en unknown
- 2016-07-05 EA EA201890172A patent/EA037092B1/ru not_active IP Right Cessation
- 2016-07-05 EP EP16734676.6A patent/EP3319983A1/en active Pending
- 2016-07-05 SG SG10202010735PA patent/SG10202010735PA/en unknown
- 2016-07-05 PE PE2017002750A patent/PE20180481A1/es unknown
- 2016-07-05 MA MA41670A patent/MA41670A1/fr unknown
- 2016-07-05 MA MA042377A patent/MA42377A/fr unknown
- 2016-07-05 MX MX2017015817A patent/MX2017015817A/es unknown
- 2016-07-05 BR BR112017028102A patent/BR112017028102A2/pt active Search and Examination
- 2016-07-05 WO PCT/EP2016/065813 patent/WO2017005734A1/en active Application Filing
- 2016-07-05 MY MYPI2018700043A patent/MY193677A/en unknown
- 2016-07-05 US US15/742,087 patent/US10287343B2/en active Active
- 2016-07-05 UA UAA201711739A patent/UA124616C2/uk unknown
- 2016-07-05 CA CA2991451A patent/CA2991451A1/en active Pending
- 2016-07-05 CN CN201680039795.4A patent/CN107849104B/zh active Active
- 2016-07-06 UY UY0001036773A patent/UY36773A/es not_active Application Discontinuation
- 2016-07-06 AR ARP160102045A patent/AR105267A1/es unknown
- 2016-07-06 TW TW105121455A patent/TWI745295B/zh active
2017
- 2017-12-04 PH PH12017502207A patent/PH12017502207A1/en unknown
- 2017-12-18 CO CONC2017/0012971A patent/CO2017012971A2/es unknown
2018
- 2018-01-01 IL IL256685A patent/IL256685B/en unknown
- 2018-01-03 ZA ZA2018/00027A patent/ZA201800027B/en unknown
- 2018-01-05 CL CL2018000043A patent/CL2018000043A1/es unknown
- 2018-01-05 EC ECIEPI2018887A patent/ECSP18000887A/es unknown
- 2018-05-10 HK HK18106080.8A patent/HK1246804A1/zh unknown
2019
- 2019-05-13 US US16/409,945 patent/US10889640B2/en active Active
- 2019-12-06 JP JP2019220807A patent/JP7100008B2/ja active Active
2020
- 2020-12-29 US US17/136,189 patent/US11732034B2/en active Active
2022
- 2022-06-30 JP JP2022105415A patent/JP7413448B2/ja active Active
2023
- 2023-06-30 US US18/344,945 patent/US20230416350A1/en active Pending

Also Published As

Publication number	Publication date
EA201890172A1 (ru)	2018-10-31
PH12017502207A1 (en)	2018-06-11
US20230416350A1 (en)	2023-12-28
JP6630426B2 (ja)	2020-01-15
AU2016289755A1 (en)	2018-01-04
JP2022141689A (ja)	2022-09-29
UY36773A (es)	2017-01-31
US10889640B2 (en)	2021-01-12
MX2017015817A (es)	2018-04-10
US20180201666A1 (en)	2018-07-19
US20210115121A1 (en)	2021-04-22
CN107849104A (zh)	2018-03-27
WO2017005734A1 (en)	2017-01-12
EA037092B1 (ru)	2021-02-04
ZA201800027B (en)	2019-06-26
MA42377A (fr)	2018-05-16
CA2991451A1 (en)	2017-01-12
BR112017028102A2 (pt)	2018-09-04
AU2016289755C1 (en)	2021-08-19
NZ738058A (en)	2021-07-30
TWI745295B (zh)	2021-11-11
KR20180025962A (ko)	2018-03-09
TN2017000539A1 (en)	2019-04-12
HK1246804A1 (zh)	2018-09-14
AU2016289755B2 (en)	2020-12-03
JP7413448B2 (ja)	2024-01-15
PE20180481A1 (es)	2018-03-07
US20190284267A1 (en)	2019-09-19
US10287343B2 (en)	2019-05-14
CN107849104B (zh)	2021-08-27
EP3319983A1 (en)	2018-05-16
US11732034B2 (en)	2023-08-22
CL2018000043A1 (es)	2018-05-18
UA124616C2 (uk)	2021-10-20
JP2018524001A (ja)	2018-08-30
IL256685A (en)	2018-03-29
CO2017012971A2 (es)	2018-03-09
JP2020055849A (ja)	2020-04-09
IL256685B (en)	2022-02-01
AR105267A1 (es)	2017-09-20
JP7100008B2 (ja)	2022-07-12
MA41670A1 (fr)	2018-05-31
ECSP18000887A (es)	2018-03-31
MY193677A (en)	2022-10-25
TW201713689A (zh)	2017-04-16

Publication	Publication Date	Title
HK1256116A1 (zh)	2019-09-13	抗lag-3抗體
HK1253507A1 (zh)	2019-06-21	抗 ror1 抗體
HK1254836A1 (zh)	2019-07-26	抗-ror1抗體
GB201521393D0 (en)	2016-01-20	Antibodies
GB201521391D0 (en)	2016-01-20	Antibodies
IL253633B (en)	2021-06-30	Anti-transthyretin antibodies
HK1246804A1 (zh)	2018-09-14	Tau結合抗體
GB201521382D0 (en)	2016-01-20	Antibodies
ZA201705662B (en)	2018-08-29	Anti-transthyretin antibodies
HK1255056A1 (zh)	2019-08-02	抗cd115抗體
IL255323A0 (en)	2017-12-31	Anti-fcrn antibodies
SG11201706126WA (en)	2017-08-30	Anti-transthyretin antibodies
GB201509907D0 (en)	2015-07-22	Antibodies
GB201522394D0 (en)	2016-02-03	Antibodies
GB201503438D0 (en)	2015-04-15	Antibodies
IL284022B1 (en)	2023-05-01	Anti-transthyretin antibodies
GB201518728D0 (en)	2015-12-09	Antibodies
GB201515572D0 (en)	2015-10-14	Anti-LAG-3 antibodies
GB201515570D0 (en)	2015-10-14	Anti-LAG-3 antibodies
GB201514425D0 (en)	2015-09-30	Antibodies
GB201508444D0 (en)	2015-07-01	Antibodies
GB201508437D0 (en)	2015-07-01	Antibodies
GB201507541D0 (en)	2015-06-17	Antibodies
GB201504858D0 (en)	2015-05-06	Antibodies
GB201502591D0 (en)	2015-04-01	Antibodies